Uterussarkome are a group of highly malignant tumors unterschiedlichster that develop from the corpus uteri.

Sarcomas account for <5% of uterine malignancies. The risk factors are similar to those for endometrial cancer (etiology). The most common types are mixed mesodermal tumors (carcinosarcoma, a mixture of sarcoma and adenocarcinoma, formerly known as malignant Mullerian mixed tumor), leiomyosarcoma and endometrial stromal tumors.

Uterussarkome are a group of highly malignant tumors unterschiedlichster that develop from the corpus uteri. Sarcomas account for <5% of uterine malignancies. The risk factors are similar to those for endometrial cancer (etiology). The most common types are mixed mesodermal tumors (carcinosarcoma, a mixture of sarcoma and adenocarcinoma, formerly known as malignant Mullerian mixed tumor), leiomyosarcoma and endometrial stromal tumors. Symptoms and signs Most sarcomas manifest with abnormal vaginal bleeding, rarely with pelvic pain or a palpable pelvic mass. Diagnostic Transvaginal ultrasound and endometrial biopsy or fractional curettage The symptoms usually lead to a transvaginal ultrasound and endometrial biopsy or fractional curettage. In patients with previously identified tumor preoperative CT or MRI is usually done. The staging is done intraoperatively: Stage I: Confined to corpus uteri Stage II: Limited to corpus uteri and cervix Stage III: spread across the uterus out, but on the basin limited Stage IV: spread outside the pelvis or in the mucosa of the urinary bladder and rectum forecast The prognosis is usually worse than patients with endometrial cancer comparable stages. In ectopic tumor extension, the survival time is short. Histology is not an independent prognostic factor. In one study, the 5-year survival rates were in stage I of 51% in stage II 13%, Stage III 10%, and Stage IV at 3%. Most of the tumors recur locally, in the abdomen or in the lungs. Treatment Total abdominal hysterectomy, bilateral Salpingoovarektomie and complete examination of the abdomen Treatment consists of complete abdominal hysterectomy and bilateral Salpingoovarektomie with complete examination of the abdomen. In patients with carcinosarcoma the pelvic and para-aortic lymph nodes are removed. The benefit of lymphadenectomy in patients with leiomyosarcoma or endometrial stromal tumor is controversial; it had not been established therapeutic benefit. Typically, adjuvant radiotherapy is performed, the local recurrence seems to delay, but does not affect overall survival. Chemotherapy drugs are usually given at an advanced stage or recurrent disease; they vary with the type of tumor. Most patients with carcinosarcoma treated with carboplatin plus paclitaxel. The standard treatment for leiomyosarcoma consists of gemcitabine plus docetaxel. The overall response is, however bad, although progestins are often effective in endometrial stromal tumors.

Health Life Media Team

Leave a Reply